Prevention of Cancer

Risk Assessment through Precision Screening and Genetic Insights.

Boost survival with early detection. Our MammoReady™ and Hereditary Cancer Tests identify high-risk individuals, enabling proactive, accurate care to reduce cancer risk and take control of your health.

  • Improved Survival: Early cancer detection leads to higher survival rates through proactive treatment.
  • Personalized Screening: Genetic insights provide targeted screening based on individual risk factors.
Product Hero Image
Science Behind It image
Science Behind It

Backed by Science, Built for You

Improving screening and early detection in cancer significantly increases survival rate.

Cancer Stage% Cases Diagnosed (Average)5-Year Survival Rate (%)
Stage I2.4294.3
Stage II18.2175
Stage III32.3331
Stage IV47.7111.7

Cancer arises due to genetic mutations, which can be inherited (germline) or acquired (somatic).

Germline sequencing can identify individuals who are at higher risk. Based on the Chinese Health Study, 51% more cancers can be detected if screening was more targeted based on their risk profiles, compared to random screening of 35% of the population.

Indication of Use

Who Can Benefit from this?

Although almost all individuals can take the test, our tests are especially helpful for individuals who have primary family history.

MammoReady™

Breast cancer risk assessment for early screening (ages 35-49).

Hereditary Cancer Test

Identifies inherited cancer risks for preventive care.

Test Performance

Why Choose Us

We can help you:

Test Performance image 1

MammoReady

High accuracy in breast cancer risk stratification.

Test Performance image 2

Hereditary Cancer Panel

100% sensitivity, 99.9% specificity.

Product Logistics of the test Image
Logistic of the Test

Fast, Secure, & Science-Backed Testing

MammoReady:

  • Sample Type Buccal Swab
  • Turnaround Time is 2-4 Weeks
  • Platform using Microarray and Next-generation Sequencing
  • Result availability on Nala Clinical Decision and Nala PHM
  • Analysis at Nalagenetics Pte Ltd (Indonesia)

Strand:

  • Sample Type Whole Blood
  • Tunraround Time is 21 days
  • Platform using Next-generation Sequencing
  • Result availability on PDF Report via email
  • Analysis at Strand Life Science (India)
Your Journey

What Happens After You Get Your Results?

Your Journey image 1

Your Journey image 2
Guidelines from Experts

Backed by Science, Trusted by Experts

Guideline image 1

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancers:

BRCA1/2 dan Gen Lain dengan Penetrasi Tinggi: NCCN merekomendasikan pengujian genetik untuk individu dengan riwayat pribadi atau keluarga yang menunjukkan kemungkinan sindrom kanker payudara, ovarium, atau pankreas herediter. I...

Guideline image 2

Colorectal Cancer (CRC):

Rekomendasi Pengujian Universal: Pedoman NCCN terbaru menganjurkan pengujian panel multigen garis keturunan untuk semua individu yang didiagnosis dengan Kanker Kolorektal (CRC) sebelum usia 50 tahun. Selain itu, pengujian juga ...

Guideline image 3

Pancreatic Cancer:

Pengujian Garis Keturunan Universal: NCCN merekomendasikan agar semua pasien dengan kanker pankreas menjalani pengujian genetik garis keturunan, terlepas dari riwayat keluarga, karena prevalensi mutasi garis keturunan yang sign...

Guideline image 4

Prostate Cancer:

Pengujian pada Penyakit Lanjut: Untuk pria yang menunjukkan kanker prostat regional atau metastatik, NCCN menyarankan pengujian garis keturunan untuk mengidentifikasi potensi sindrom kanker herediter yang dapat memengaruhi kepu...

What Report Do I Get?

Strand

With 10% of cancers being hereditary and survival rates dropping from >90% at Stage 1 to <30% at Stage 4, early detection is key. Our genomic test helps identify high-risk individuals for precise treatment and better outcomes.​

  • 98% sensitivity & specificity

  • Covers 30+ hereditary cancer genes by ACMG & NCCN
  • Offers ACMG-recommended cancer screening (breast, ovarian, pancreatic, prostate, colorectal, endometrial)
what-you-get-image

MammoReady™

MammoReady™ helps you understand your breast cancer risk and take proactive steps.

This test provides a genetic report covering three types of risks :

  • Polygenic RIsk: Using a model designed for breast cancer, we examine 313 single nucleotide
  • Monogenic Risk: Focuses on key genes associated with breast cancer, including BRCA 1, BRCA 2, and PALB2.
  • Clinical Risk: Includes family history, lifestyle, and medical history.
what-you-get-image
Get Your Test Now

Better Health, Backed by Genetics - At the Right Price

Choose the right package for you:

MammoReady™ image
MammoReady™

Early Detection Starts with You: Get MammoReady™ for Proactive Breast Cancer Prevention

Hereditary Cancer Screening image
Hereditary Cancer Screening

Book a consultation with our doctor and start your journey with our test.

Find the right DNA test for you and your loved ones

Unlock total genetic insights to guide your health, nutrition, and wellness journey with personalized and preventive precision